Key Development
GSK plans to close its vaccine manufacturing facility in Dresden, Germany, in the summer of 2027, putting 641 jobs at risk. The underlying issue goes beyond conventional cost cutting: declining demand for traditional egg-based influenza vaccines has left the company with more manufacturing capacity than it expects to need. Following a review of its influenza manufacturing sites in Dresden and Ste-Foy, Canada, GSK selected Canada as the location capable of meeting anticipated demand on a sustainable and competitive basis.
Dresden has long been part of GSK’s European vaccine manufacturing footprint, producing influenza vaccines alongside activities related to hepatitis vaccines. Yet while GSK is reducing legacy influenza capacity, it is simultaneously preparing to advance its mRNA seasonal influenza candidate into Phase III following positive Phase II results.
Taken together, the message is clear: GSK is not retreating from influenza vaccines. It is repositioning how it intends to compete in them.
Why It Matters
- Technology is beginning to redefine manufacturing assets. Plants optimized around established production platforms can become economically less attractive as portfolios migrate toward more flexible technologies.
- This is a capital-allocation decision, not simply a workforce story. Maintaining duplicated capacity becomes difficult to justify when demand is structurally weakening.
- mRNA is moving deeper into seasonal influenza. GSK plans to begin Phase III testing of its mRNA flu candidate in September 2026, reinforcing the transition toward competition based on platform performance and adaptability.
- Europe faces a strategic-autonomy dilemma. Policymakers want vaccine manufacturing capacity to remain within Europe for health-security reasons, while manufacturers must still rationalize sites that are commercially or technologically less competitive.
Healthcare Insight Analysis
The Dresden decision highlights an increasingly important distinction between manufacturing capacity and strategically relevant manufacturing capacity.
Egg-based influenza manufacturing is far from obsolete. WHO estimates that more than 80% of seasonal and pandemic influenza vaccine production still relies on egg-based processes. However, WHO has also highlighted limitations around supply chains and rapid scale-up, while pointing toward cell-based, recombinant and next-generation mRNA technologies as important areas for future capacity development.
For GSK, closing Dresden while advancing an mRNA candidate can therefore be interpreted as portfolio architecture in action. Capital is moving away from excess capacity associated with an established platform and toward technologies that could offer greater flexibility in strain selection, development timelines and future manufacturing configurations.
If next-generation influenza vaccines prove clinically and commercially successful, manufacturing economics could change substantially. Competitive advantage may increasingly depend not simply on the number of doses a company can produce, but on how quickly its platform can be updated, validated and scaled.
The decision also exposes a broader policy tension. Governments increasingly regard domestic pharmaceutical manufacturing as part of national and regional security. Companies, however, allocate capital according to utilization, productivity and technological relevance. Maintaining strategic capacity will therefore require mechanisms that make preparedness economically sustainable rather than assuming companies will preserve redundant facilities indefinitely.
Market Implications
For vaccine manufacturers: legacy plants will face growing pressure either to demonstrate superior economics or to justify investment in technological modernization.
For CDMOs and manufacturing investors: value may increasingly migrate toward modular, multi-product and multi-platform facilities capable of rapid switching and scale-up.
For Europe: vaccine sovereignty will require more than preserving physical factories. The priority will be maintaining technologically relevant, rapidly deployable manufacturing capacity.
For GSK: Dresden reduces its physical manufacturing footprint, but the decision may ultimately represent something more strategic — a transfer of capital from yesterday’s capacity toward tomorrow’s influenza platform.